PLoS ONE
December 2, 2010
Gantt P. Galloway, Jennifer D. Siegrist, Lynn C. Robertson et al.
22 citations
A double-blind placebo-controlled study found that the hallucinogen MDA increases closed-eye visions and mystical-type experiences. People who had more intense visions tended to perform worse on tests of contour integration and object recognition, suggesting that drug-induced hallucinations may be stronger in individuals with poorer perceptual processing. This points to possible shared mechanisms with hallucinations in psychiatric and neurological conditions.
bioRxiv (Cold Spring Harbor Laboratory)
June 23, 2015
Matthew J. Baggott, Jeremy Coyle, Jennifer D. Siegrist et al.
21 citations
preprint
MDMA produces a prosocial syndrome that facilitates emotional disclosure by increasing feelings of authenticity and decreasing concerns about negative evaluation by others. In a within-subjects double-blind placebo controlled study of 1.5 mg/kg oral MDMA, the drug showed both sedative- and stimulant-like effects, including increased self-report anxiety, but positively altered self-evaluation and reduced social anxiety. MDMA also increased how comfortable participants felt describing emotional memories, consistent with the suggestion that it represents a novel pharmacological class.
Journal of Psychoactive Drugs
March 15, 2019
Matthew J. Baggott, Kathleen J. Garrison, Jeremy Coyle et al.
20 citations
The drug MDA, an entactogen similar to MDMA (ecstasy), produces longer-lasting emotional and physiological effects than MDMA. In a controlled experiment with healthy volunteers, a single oral dose of 1.4 mg/kg MDA increased heart rate, blood pressure, and stress hormones (cortisol and prolactin) to levels comparable to those from a 1.5 mg/kg dose of MDMA. However, participants' self-reported drug effects from MDA remained elevated for at least 8 hours, whereas MDMA effects subsided by 6 hours. Blood measurements showed that MDA and its metabolite HMA reached peak concentrations of about 229 µg/L and 92 µg/L, respectively. Because the two drugs had similar blood-level profiles, the longer duration of MDA's effects likely stems from differences in how it acts on the brain rather than from slower elimination.